Prologue References
1. IDF. International Diabetes Federation. IDF Diabetes Atlas. 6th edition ed. Brussels, Belgium, 2014.
2. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23(10): 1516–26.
3. Patterson C, Guariguata L, Dahlquist G, Soltesz G, Ogle G, Silink M. Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Research and Clinical Practice 2014; 103(2): 161–75.
4. Tamayo T, Rosenbauer J, Wild SH, Spijkerman AM, Baan C, Forouhi NG, et al. Diabetes in Europe: an update. Diabetes Research and Clinical Practice 2014; 103(2): 206–17.
5. Majeed A, El-Sayed AA, Khoja T, Alshamsan R, Millett C, Rawaf S. Diabetes in the Middle-East and North Africa: an update. Diabetes Research and Clinical Practice 2014; 103(2): 218–22.
6. Yisahak SF, Beagley J, Hambleton IR, Narayan KM. Diabetes in North America and the Caribbean: an update. Diabetes Research and Clinical Practice 2014; 103(2): 223–30.
7. Aschner P, Aguilar-Salinas C, Aguirre L, Franco L, Gagliardino JJ, de Lapertosa SG, et al. Diabetes in South and Central America: an update. Diabetes Research and Clinical Practice 2014; 103(2): 238–43.
8. Ramachandran A, Snehalatha C, Ma RC. Diabetes in South-East Asia: an update. Diabetes Research and Clinical Practice 2014; 103(2): 231–7.
9. Peer N, Kengne AP, Motala AA, Mbanya JC. Diabetes in the Africa Region: an update. Diabetes Research and Clinical Practice 2014; 103(2): 197–205.
10. Chan JC, Cho NH, Tajima N, Shaw J. Diabetes in the Western Pacific Region: past, present and future. Diabetes Research and Clinical Practice 2014; 103(2): 244–55.
11. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35(3): 556–64.
12. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 2010; 304(6): 649–56.
13. Ghamdi A, Rabiu M, Hajar S, Yorston D, Kuper H, Polack S. Rapid assessment of avoidable blindness and diabetic retinopathy in Taif, Saudi Arabia. British Journal of Ophthalmology 2012; 96(9): 1168–72.
14. Burgess PI, MacCormick IJ, Harding SP, Bastawrous A, Beare NA, Garner P. Epidemiology of diabetic retinopathy and maculopathy in Africa: a systematic review. Diabetic Medicine 2013; 30(4): 399–412.
15. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. British Journal of Ophthalmology 2015; 99(1):64–8.
16. Wu X, Liu L, Geng J, Yuan Z, Shan Z, Chen L. Prevalence of diabetic retinopathy in mainland China: A meta-analysis. PLoS ONE 2012; 7(9).
17. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008; 115(11): 1869–75.
18. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Investigative Ophthalmology and Visual Science 2005; 46(7): 2328–33.
19. Villena JE, Yoshiyama CA, Sanchez JE, Hilario NL, Merin LM. Prevalence of diabetic retinopathy in Peruvian patients with type 2 diabetes: results of a hospital-based retinal telescreening program. Revista Panamericana de Salud Publica (Pan American Journal of Public Health)2011; 30(5): 408–14.
20. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 2003; 26(6): 1731–7.
21. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care 2003; 26(9): 2604–8.
22. Bek T, Lund-Andersen H, Hansen AB, Johnsen KB, Sandbaek A, Lauritzen T. The prevalence of diabetic retinopathy in patients with screen-detected type 2 diabetes in Denmark: the ADDITION study. Acta Ophthalmologica 2009; 87(3): 270–4.
23. Pang C, Jia L, Jiang S, Liu W, Hou X, Zuo Y, et al. Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study. Diabetes/Metabolism Researchand Reviews 2012; 28(3): 276–83.
24. Kernell A, Dedorsson I, Johansson B, Wickstrom CP, Ludvigsson J, Tuvemo T, et al. Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study. Diabetologia 1997; 40(3): 307–10.
25. Donaghue KC, Fairchild JM, Chan A, Hing SJ, Howard NJ, Silink M. Diabetes complication screening in 937 children and adolescents. Journal of Pediatr Endocrinology and Metabolism 1999; 12(2): 185–92.
26. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115(11): 1859–68.
27. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116(3): 497–503.
28. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009; 32(12): 2307–13.
29. Chase HP, Garg SK, Jackson WE, Thomas MA, Harris S, Marshall G, et al. Blood pressure and retinopathy in type I diabetes. Ophthalmology 1990; 97(2): 155–9.
30. Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF. A nationwide cross–sectional study of retinopathy and microalbuminuria in young Norwegian type 1 (insulin–dependent) diabetic patients. Diabetologia 1992; 35(11): 1049–54.
31. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44(2): 156–63.
32. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Archives of Ophthalmology 2004; 122(11): 1631–40.
33. Spalter HF. Photocoagulation of circinate maculopathy in diabetic retinopathy. American Journal of Ophthalmology 1971; 1(1 Part 2): 242–50.
34. DRS. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1976; 81(4): 383–96.
35. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978; 85(1): 82–106.
36. DRS. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88(7): 583–600.
37. The Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. Archives of Ophthalmology 1979; 97(4): 654–5.
38. The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. International Ophthalmology Clinics 1987; 27(4): 239–53.
39. ETDRS. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Archives of Ophthalmology 1985; 103(12): 1796–806.
40. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94(7): 761–74.
41. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98(5 Suppl): 823–33.
42. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991; 98(5 Suppl): 807–22.
43. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991; 98(5 Suppl): 786–806.
44. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98(5 Suppl): 766–85.
45. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991; 98(5 Suppl): 757–65.
46. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991; 98(5 Suppl): 741–56.
47. Early Treatment Diabetic Retinopathy Study Research Group. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Ophthalmology 1991; 98(5 Suppl): 834–40.
48. Smiddy WE, Flynn HW, Jr. Vitrectomy in the management of diabetic retinopathy. Survey of Ophthalmology 1999; 43(6): 491–507.
49. Blankenship GW, Machemer R. Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 1985; 92(4): 503–6.
50. Thompson JT, de Bustros S, Michels RG, Rice TA, Glaser BM. Results of vitrectomy for proliferative diabetic retinopathy. Ophthalmology 1986; 93(12): 1571–4.
51. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic vitreous hemorrhage. Archives of Ophthalmology 1987; 105(2): 191–5.
52. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Archives of Ophthalmology 1987; 105(4): 497–502.
53. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction-rhegmatogenous retinal detachment. Archives of Ophthalmology 1987; 105(4): 503–7.
54. Sigurdsson H, Baines PS, Roxburgh ST. Vitrectomy for diabetic eye disease. Eye 1988; 2 (Pt 4): 418–23.
55. The Early Treatment Diabetic Retinopathy Study Research Group. Flynn HW, Jr., Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL, 3rd. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. Ophthalmology 1992; 99(9): 1351–7.
56. Nakazawa M, Kimizuka Y, Watabe T, Kato K, Watanabe H, Yamanobe S, et al. Visual outcome after vitrectomy for diabetic retinopathy. A five-year follow-up. Acta Ophthalmologica (Copenh) 1993; 71(2): 219–23.
57. Karel I, Kalvodova B. Long-term results of pars plana vitrectomy and silicone oil for complications of diabetic retinopathy. European Journal of Ophthalmology 1994; 4(1): 52–8.
58. Harbour JW, Smiddy WE, Flynn HW, Jr., Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. American Journal of Ophthalmology 1996; 121(4): 405–13.
59. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. American Journal of Ophthalmology 2000; 130(2): 178–86.
60. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefe’s Archive for Clinical and Experimental Ophthalmology 2001; 239(4): 264–70.
61. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. American Journal of Ophthalmology 2001; 132(3): 369–77.
62. Amino K, Tanihara H. Vitrectomy combined with phacoemulsification and intraocular lens implantation for diabetic macular edema. Japan Journal of Ophthalmology 2002; 46(4): 455–9.
63. Lewis H. The role of vitrectomy in the treatment of diabetic macular edema(Editorial). American Journal of Ophthalmology 2001; 131(1): 123–25.
64. Lahey JM, Francis RR, Kearney JJ. Combining phacoemulsification with pars plana vitrectomy in patients with proliferative diabetic retinopathy: a series of 223 cases. Ophthalmology 2003; 110(7): 1335–9.
65. Treumer F, Bunse A, Rudolf M, Roider J. Pars plana vitrectomy, phacoemulsification and intraocular lens implantation. Comparison of clinical complications in a combined versus two-step surgical approach. Graefe’s Archives of Clinical and Experimental Ophthalmology 2006; 244(7): 808–15.
66. Schrey S, Krepler K, Wedrich A. Incidence of rhegmatogenous retinal detachment after vitrectomy in eyes of diabetic patients. Retina 2006; 26(2): 149–52.
67. Diolaiuti S, Senn P, Schmid MK, Job O, Maloca P, Schipper I. Combined pars plana vitrectomy and phacoemulsification with intraocular lens implantation in severe proliferative diabetic retinopathy. Ophthalmic Surgery, Lasers and Imaging Retina 2006; 37(6): 468–74.
68. Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117(6): 1087–93 e3.
69. Tao Y, Jiang YR, Li XX, Gao L, Jonas JB. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment. Retina 2010; 30(3): 447–51.
70. Gupta B, Wong R, Sivaprasad S, Williamson TH. Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye 2012; 26(4): 576–82.
71. Ostri C, Lux A, Lund-Andersen H, la Cour M. Long-term results, prognostic factors and cataract surgery after diabetic vitrectomy: a 10-year follow-up study. Acta Ophthalmologica 2014; 92(6): 571–6.
72. Barsam A, Laidlaw A. Visual fields in patients who have undergone vitrectomy for complications of diabetic retinopathy. A prospective study. BMC Ophthalmology 2006; 6: 5.
73. Zhang ZH, Liu HY, Hernandez-Da SES, Romano MR, Falavarjani KG, Ahmadieh H, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. American Journal of Ophthalmology 2013; 156(1): 106–15.e2.
74. Liu H, Li X, Pu W. Intravitreal bevacizumab as a preoperative adjunct in vitrectomy for proliferative diabetic retinopathy: a meta-analysis. Journal China Medical University 2012; 41(9): 830–33.
75. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. British Journal of Ophthalmology 2011; 95(9): 1216–22.
76. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 2014; 4(2): e004015.